Continuous technological advancements in PCR technologies & dPCR and qPCR Market Development
Market growth influenced due to following factors:
- Rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders.
- Continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments.
- Increasing investments, funds, and grants for genomic research.
- Increasing use of biomarker profiling for disease diagnostics.
Global market size:
According to research report the dPCR and qPCR market is projected to reach $6.3 billion by 2024, growing at a CAGR of 8.8%.
The major players operating in the dPCR qPCR Market are Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).
Top Market Segments:
The qPCR reagents & consumables segment is expected to command the largest share of the qPCR products & services market. Factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life sciences research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples) are expected to drive the growth of the qPCR reagents and consumables market.
The hospitals and diagnostic centres segment are expected to dominate the qPCR market in 2019. The large share of this segment is attributed to the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness on the benefits of qPCR.
North America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019. The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R&D funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204